和邦生物1月30日获融资买入1.12亿元，融资余额6.32亿元

Core Viewpoint - On January 30, Hebang Biotechnology experienced a decline of 5.24% with a trading volume of 1.351 billion yuan, indicating a significant market reaction to its financial performance and trading activities [1]. Financing Summary - On January 30, Hebang Biotechnology had a financing buy-in of 112 million yuan and a financing repayment of 151 million yuan, resulting in a net financing outflow of 39.02 million yuan [1]. - As of January 30, the total balance of margin trading for Hebang Biotechnology was 641 million yuan, with a financing balance of 632 million yuan, accounting for 2.83% of its market capitalization, which is above the 90th percentile of the past year [1]. - In terms of securities lending, on January 30, Hebang Biotechnology had a repayment of 424,700 shares and a sell-out of 234,200 shares, with a sell-out amounting to 592,500 yuan at the closing price [1]. Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province. Its main business includes the manufacturing of pesticides and pesticide intermediates, fine chemical products, intelligent glass, special glass, and the development of soda ash, ammonium chloride, and mineral resources [1]. - The revenue composition of Hebang Biotechnology is as follows: chemical products account for 85.89%, photovoltaic glass and other products for 17.61%, mineral products for 6.74%, and other businesses for 5.02% [1]. Financial Performance - As of September 30, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, while the average circulating shares per person increased by 2.03% to 44,939 shares [2]. - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.11 million yuan, down 57.93% year-on-year [2]. Dividend Information - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders of Hebang Biotechnology, the Penghua CSI Segmented Chemical Industry Theme ETF Connect A (014942) is the fourth largest shareholder with 92.788 million shares, marking a new entry [3]. - The Southern CSI 500 ETF (510500) is the fifth largest shareholder with 90.090 million shares, having decreased by 2.1844 million shares compared to the previous period [3]. - The Hong Kong Central Clearing Limited is the sixth largest shareholder with 89.2826 million shares, having increased by 1.60908 million shares from the previous period [3].